Hyperparathyroidism is a condition in which the parathyroid glands produce excess parathyroid hormone (PTH), resulting in high calcium levels in the blood. It can cause symptoms like weakness, fatigue, abdominal pain, poor appetite, nausea or vomiting and kidney stones. The hyperparathyroidism treatment market includes products and therapies used for the management and treatment of hyperparathyroidism such as parathyroid surgery, medications, and vitamin & mineral supplements. Parathyroidectomy is the most common and effective treatment for hyperparathyroidism involving surgical removal of all or part of the parathyroid gland. Drug treatment includes calcimimetics such as cinacalcet which helps reduce the production of PTH. Vitamin D and calcium supplements are also given to patients.
The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 780.1 Mn in 2024 and is expected to reach USD 991.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
Key Takeaways
Key players operating in the hyperparathyroidism treatment are AbbVie, Entera Bio, GlaxoSmithKline, Teva Pharmaceutical Industries, Amgen, Novartis, OPKO Health.
The rising geriatric population is one of the major driving factors for the hyperparathyroidism treatment market. As per the United Nations (UN), the number of people aged 60 years and above is estimated to reach 2.1 billion by 2050 from 1.1 billion in 2020. The risk of hyperparathyroidism increases with age.
Asia Pacific region offers significant Hyperparathyroidism Treatment Market Growth opportunities for players is due to growing healthcare investment and expansion of key companies in the region. For instance, in May 2021, Entera Bio announced plans to expand clinical trials for its hyperparathyroidism drug EB613 to China.
Market drivers -
The rising geriatric population across the globe coupled with increasing prevalence of hyperparathyroidism is a key market driver. As per studies, hyperparathyroidism affects approximately 1 in 1000 people over 60 years old and is more common in women than men.
Market restraints -
High costs associated with parathyroidectomy surgery and limited reimbursements are some of the major restraints for the hyperparathyroidism treatment market. Given its nature as an uncommon endocrine disorder, the large costs of treatment pose significant barriers.
Segment Analysis
The hyperparathyroidism treatment market is segmented based on drug, indication, and distribution channel. The drug segment is further segmented into parathyroid hormone antagonists, vitamin D analogs, and calcium supplements. The parathyroid hormone antagonists segment dominates the market as these drugs can effectively reduce serum calcium and parathyroid hormone levels in patients with moderate to severe hyperparathyroidism. The market is also segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism based on indication. The primary hyperparathyroidism indication segment holds the largest market share due to the rising prevalence of the condition. The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment leads the market owing to the high patient preference for these distribution channels.
Global Analysis
The North American region currently dominates the hyperparathyroidism treatment market owing to the rising prevalence of primary hyperparathyroidism, growing aging population, increasing adoption of healthcare insurance, and availability of advanced treatment options in the region. The Asia Pacific region is projected to witness the highest growth rate over the forecast period due to the improving healthcare infrastructure, growing awareness about hyperparathyroidism treatment, and increasing healthcare expenditure in emerging Asian countries. Some of the fastest growing hyperparathyroidism treatment markets in Asia Pacific include India, China, and Japan.
Get This Report in Japanese Language: 副甲状腺機能亢進症治療市場
Get This Report in Korean Language: 부갑상선기능항진증 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
